Edition:
United Kingdom

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

153.68USD
21 Sep 2018
Change (% chg)

$2.21 (+1.46%)
Prev Close
$151.47
Open
$151.66
Day's High
$154.26
Day's Low
$151.66
Volume
738,672
Avg. Vol
283,544
52-wk High
$156.82
52-wk Low
$100.20

Latest Key Developments (Source: Significant Developments)

Edwards Lifesciences Reports Q2 Earnings Of $1.32/Share
Thursday, 26 Jul 2018 

July 26 (Reuters) - Edwards Lifesciences Corp ::QUARTERLY EARNINGS PER SHARE $1.32.QUARTERLY ADJUSTED EARNINGS PER SHARE $1.24.QUARTERLY SALES $944 MILLION, UP 12 PERCENT.QUARTERLY TOTAL ADJUSTED SALES $972 MILLION, UP 10 PERCENT.SAYS 2018 ADJUSTED. EARNINGS PER SHARE OUTLOOK RAISED TO $4.60-$4.75 FROM $4.50-$4.70.SAYS CONFIDENT IN ACHIEVING HIGHER END OF 2018 SALES OUTLOOK RANGE OF $3.5 BILLION-$3.9 BILLION.SEES Q3 TOTAL SALES OF $900 MILLION-$950 MILLION.SEES Q3 ADJUSTED EARNINGS PER SHARE OF $0.93-$1.03.QUARTERLY TRANSCATHETER HEART VALVE THERAPY SALES OF $585 MILLION, UP 20 PERCENT.Q2 EARNINGS PER SHARE VIEW $1.14, REVENUE VIEW $969.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.63, REVENUE VIEW $3.84 BILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $934.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing
Monday, 30 Apr 2018 

April 30 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING.EDWARDS LIFESCIENCES SAYS NEW AGREEMENT TO REPLACE THE EXISTING $750 MILLION UNSECURED REVOLVING CREDIT FACILITY UNDER THE 2014 CREDIT AGREEMENT.EDWARDS LIFESCIENCES - MAY INCREASE AMOUNT OF REVOLVING CREDIT FACILITY UNDER CREDIT AGREEMENT BY UP TO ADDITIONAL $250 MILLION IN THE AGGREGATE.  Full Article

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Monday, 16 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016
Thursday, 29 Mar 2018 

March 29 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING.  Full Article

Edwards Lifesciences Corp Acquires Harpoon Medical
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Edwards Lifesciences Corp ::EDWARDS ACQUIRES HARPOON MEDICAL.EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1.EDWARDS LIFESCIENCES - THERE IS POTENTIAL FOR UP TO $150 MILLION IN MILESTONE PAYMENTS OVER NEXT 10 YEARS AS PART OF DEAL.EDWARDS LIFESCIENCES - JAMES GAMMIE HAD AN EQUITY INTEREST IN HARPOON MEDICAL, AND WILL SERVE AS A CONSULTANT TO EDWARDS LIFESCIENCES.  Full Article

Edwards Lifesciences reports quarterly share of $0.79
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Edwards Lifesciences Corp ::Edwards Lifesciences - Qtrly earnings per share $0.79; Qtrly adjusted earnings per share $0.84; Qtrly sales $821.5 million, up 11.1 percent.Edwards Lifesciences - Qtrly Transcatheter Heart Valve Therapy sales of $481.2 million, up 17.3 percent.Q3 earnings per share view $0.86, revenue view $832.0 million -- Thomson Reuters I/B/E/S.Edwards lifesciences - Reaffirmed FY sales estimate at high end of $3.2 to $3.4 billion range, FY adjusted EPS estimate of $3.65 to $3.85.Edwards lifesciences - "Experienced minimal business impact" from recent natural disasters.FY2017 earnings per share view $3.78, revenue view $3.39 billion -- Thomson Reuters I/B/E/S.  Full Article

UPDATE 4-Medical device maker Stryker makes takeover approach to Boston Scientific -WSJ

June 11 Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported https://www.wsj.com/articles/stryker-has-made-a-takeover-approach-to-boston-scientific-1528727749?mod=searchresults&page=1&pos=1 on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.